Viking therapeutics, inc. (VKTX)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

15,260

8,377

30,952

19,123

14,343

24,779

169,506

34,610

36,356

8,988

2,568

3,393

4,359

3,075

3,054

5,159

3,958

768

2,140

9,497

327

755

Short-term investments – available for sale

253,901

267,261

257,120

273,513

284,375

276,741

134,656

107,556

41,112

11,587

7,270

8,689

7,954

10,075

11,562

12,036

7,292

13,335

15,349

12,162

-

-

Prepaid clinical trial and preclinical study costs

6,738

7,458

612

343

168

335

1,847

1,499

1,014

887

1,346

1,732

2,183

541

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

547

405

572

665

251

278

607

593

249

389

340

447

177

282

1,005

1,113

909

1,097

1,442

610

33

17

Total current assets

276,446

283,501

289,256

293,644

299,137

302,133

306,616

144,258

78,731

21,851

11,525

14,264

14,673

13,974

15,623

18,310

12,161

15,201

18,932

22,269

360

773

Right-of-use assets

530

598

664

730

794

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred public offering and other financing costs

99

128

173

90

120

150

180

210

240

270

275

17

439

521

614

158

515

157

-

3,070

2,408

2,268

Deposits

29

29

29

29

29

29

-

-

-

-

39

39

39

39

80

80

80

80

-

-

-

0

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80

-

0

-

Total assets

277,104

284,256

290,122

294,493

300,080

302,312

306,796

144,468

78,971

22,121

11,839

14,320

15,152

14,535

16,317

18,549

12,756

15,439

19,012

22,269

2,769

3,043

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

3,098

2,431

2,095

1,870

1,676

959

1,215

1,493

658

1,529

1,555

1,304

1,726

1,203

881

1,206

1,172

592

401

1,008

1,879

1,830

Accrued license fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24,826

19,865

Other accrued liabilities

5,135

4,044

3,802

3,468

2,961

3,591

3,528

2,612

1,889

2,257

2,837

2,418

1,655

1,237

996

852

745

1,384

1,103

119

517

380

Lease liability, current

309

302

295

288

281

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

34

22

9

59

-

34

22

10

-

-

152

121

112

77

Convertible notes payable, current portion (net of discount of $0 and $404 at December 31, 2018 and 2017, respectively)

-

-

-

-

-

-

-

-

3,721

3,451

3,180

3,050

-

3,269

2,826

2,382

-

-

1,911

1,670

310

304

Debt conversion feature liability

-

-

-

-

-

-

-

-

37

1,398

2,030

894

-

731

1,351

1,286

-

-

2,154

1,956

62

58

Total current liabilities

8,542

6,777

6,192

5,626

4,918

4,550

4,743

4,105

6,339

8,657

9,613

7,726

3,382

6,476

6,077

5,738

1,918

1,976

5,722

4,876

27,708

22,517

Accrued interest, non-current

-

-

-

-

-

-

-

-

-

-

-

-

47

-

-

-

202

183

-

-

-

-

Convertible notes payable (net of discount of $244,362 and $0 at March 31, 2017 and December 31, 2016, respectively)

-

-

-

-

-

-

-

-

-

-

-

-

3,713

-

-

-

3,139

2,151

-

-

1,429

1,264

Debt conversion feature liability

-

-

-

-

-

-

-

-

-

-

-

-

453

-

-

-

1,698

2,370

-

1,956

1,469

1,390

Deferred rent

-

-

-

-

-

12

-

-

-

-

-

6

10

16

20

24

27

31

19

-

-

-

Lease liability, net of current portion

279

360

438

513

588

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total long-term liabilities

279

360

438

513

588

12

-

-

-

-

-

6

4,224

16

20

24

5,069

4,737

19

-

2,899

2,654

Total liabilities

8,821

7,137

6,630

6,139

5,506

4,562

4,743

4,105

6,339

8,657

9,613

7,733

7,606

6,492

6,098

5,763

6,987

6,714

5,741

4,876

30,608

25,171

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

-

0

0

Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at March 31, 2020 and December 31, 2019; no shares issued and outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

-

-

-

0

Common stock, $0.00001 par value: 300,000,000 shares authorized at March 31, 2020 and December 31, 2019; 72,562,863, and 72,413,602 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

1

1

1

1

1

1

1

1

1

-

0

0

0

0

0

0

0

0

0

0

0

0

Additional paid-in capital

407,478

405,803

404,581

403,630

402,464

401,090

399,847

231,587

157,146

94,339

78,999

77,264

73,052

68,326

66,858

65,617

54,902

54,277

53,729

53,123

13

12

Accumulated deficit

-138,384

-128,697

-121,247

-115,516

-107,842

-102,918

-97,678

-91,078

-84,406

-80,855

-76,770

-70,670

-65,499

-60,277

-56,632

-52,825

-49,132

-45,545

-40,454

-35,717

-27,852

-22,141

Accumulated other comprehensive income (loss)

-812

12

157

239

-49

-423

-117

-147

-109

-20

-3

-5

-7

-6

-6

-6

-0

-7

-4

-12

-

-

Total stockholders’ equity

268,283

277,119

283,492

288,354

294,574

297,750

302,053

140,363

72,632

13,464

2,225

6,587

7,546

8,042

10,219

12,785

5,769

8,724

13,270

17,393

-27,839

-22,128

Total liabilities and stockholders’ equity

277,104

284,256

290,122

294,493

300,080

302,312

306,796

144,468

78,971

22,121

11,839

14,320

15,152

14,535

16,317

18,549

12,756

15,439

19,012

22,269

2,769

3,043